Clinical Research Protocols
CLINICAL RESEARCH PROTOCOLS FOR T-CELL LYMPHOID
MALIGNANCIES
This list of clinical research protocols relating to T-cell lymphoid
malignancies is compiled for your convenience.
Cutaneous T-cell Lymphoma
MDA-DM-94098, NCI-V95-0621
Phase I/II Pilot Study of Topical LGD1069 (a
Selective Retinoid) for Cutaneous T-cell Lymphoma (summary last modified: 12/95).
Chairperson: Madeleine D. Duvic. Lead organization: University of Texas M.D. Anderson
Cancer Center. Age range: over 18.
NU-T91-0136, NCI-T91-0136O Phase II Trial of Tretinoin
(TRA) in Patients With Mycosis Fungoides/ Sezary Syndrome (summary last modified: 08/97).
Chairperson: Timothy M. Kuzel. Lead organization: Northwestern University Robert H.
Lurie Cancer Center. Age range: over 18.
MDA-DM-96217, NCI-G97-1220 Phase I Study of Oral Peldesine
(BCX-34) in Patients With T-cell Malignancies (summary last modified: 08/97).
Chairperson: Madeleine D. Duvic. Lead organization: University of Texas M.D. Anderson
Cancer Center. Age range: 18 and over.
YALE-HIC-7862, NCI-T94-0189D Phase II Study of
Aminocamptothecin by 72-Hour Infusion for Advanced Cutaneous T-cell Lymphoma (summary last
modified: 06/96).
Chairperson: John R. Murren. Lead organization: Yale Comprehensive Cancer Center. Age
range: 18 and over.
NCI-83-C-23, NCI-T84-0153N Phase I/II Pilot Study of
Anti-Tac Antibody Immunotherapy in Adults With Tac-Positive T-cell Leukemia/Lymphoma
(summary last modified: 05/90).
Chairperson: Thomas A. Waldmann. Lead organization: Division of Clinical Sciences,
National Cancer Institute. Age range: 18 and over.
NCI-90-C-43A Phase I Study of Yttrium-90-Labeled Anti-Tac
in the Treatment of Tac-Expressing Cutaneous T-cell Lymphoma and Adult T-cell
Leukemia/Lymphoma (summary last modified: 11/91).
Chairperson: Thomas A. Waldmann. Lead organization: Division of Clinical Sciences,
National Cancer Institute. Age range: 18 and over.
SAFR-CT-MF-2, NCI-F94-0015 Phase II Study of Oral VP-16
for Stage III/IV or Recurrent Mycosis Fungoides/Sezary Syndrome With Sequential Addition
of DOX and MTX for Poorly Responding Disease (summary last modified: 01/95).
Chairperson: Nicolas Novitzky. Lead organization: University of Cape Town School of
Medicine. Age range: no age specified.
SERAGEN-93-04-11, NCI-V95-0740 Phase III Randomized,
Placebo-Controlled Study of Two Doses of the IL-2 Receptor-Targeted Cytotoxin DAB389-IL2
for Recurrent or Persistent Cutaneous T-cell Lymphoma (summary last modified: 08/97).
Chairperson: Patricia Bacha. Lead organization: Seragen, Inc. Age range: legal
consenting age.
LIGAND-L1069T-25, NCI-V97-1292 Phase III Study of
Targretin (LGD1069) Topical Gel in Patients With Refractory or Persistent Early Stage
Cutaneous T-cell Lymphoma (summary last modified: 09/97).
Chairperson: Richard C. Yocum. Lead organization: Ligand Pharmaceuticals, Inc. Age
range: 18 and over.
LIGAND-L1069-23, NCI-V97-1149 Phase II/III Study of
Targretin (LGD1069) Capsules in Patients With Refractory or Recurrent Early Stage T-cell
Lymphomas (summary last modified: 08/97).
Chairperson: Richard C. Yocum. Lead organization: Ligand Pharmaceuticals, Inc. Age
range: 18 and over.
LIGAND-L1069-24, NCI-V97-1151 Phase II/III Evaluation of
Targretin Capsules in Patients With Refractory Advanced Stage Cutaneous T-cell Lymphoma
(summary last modified: 05/97).
Chairperson: Richard C. Yocum. Lead organization: Ligand Pharmaceuticals, Inc. Age
range: 18 and over.
NCI-97-C-0110 Phase I/II Study of Yttrium Y 90 Labeled
Humanized Anti-Tac Monoclonal Antibody and Pentetic Acid Calcium for Tac-Expressing
Hematologic Malignancies Other Than Adult T-cell Leukemia (summary last modified: 10/97).
Chairperson: Jeffrey D. White. Lead organization: Division of Clinical Sciences,
National Cancer Institute. Age range: 18 and over.
E-1495 Phase III Study of Topical Therapy of Psoralen With
Phototherapy (PUVA), Nitrogen Mustard (Mechlorethamine HCL) Chemotherapy, or Total Skin
Electron Beam (TSE) Alone vs One Topical Therapy Combined With Interferon Alpha-2b for
Cutaneous T-cell Lymphoma (CTCL) (summary last modified: 08/97).
Chairperson: Timothy M. Kuzel. Lead organization: Eastern Cooperative Oncology Group.
Age range: 18 and over.
NBSG-9121, NCI-V92-0150 Phase II Trial of CLB/IFN-A for
Lymphoma and Other Lymphoproliferative Diseases Not Amenable to Potentially Curative
Therapy (summary last modified: 10/97).
Chairperson: Gamini S. Soori. Lead organization: National Biotherapy Study Group. Age
range: 18 and over.
T-cell Leukemia
NCI-96-C-0064F, NCI-T95-0042N
Phase I Study of the Immunotoxin LMB-2 in
Tac-Expressing Leukemias and Lymphomas (summary last modified: 10/97).
Chairperson: Robert Kreitman. Lead organization: Division of Basic Sciences. Age range:
18 and over.
Large Granular Lymphocyte Leukemia
NCI-95-C-0054B
Phase I Study of MOAB Mik-Beta-1 in the Treatment of T-cell Large
Granular Lymphocytic Leukemia (summary last modified: 04/97).
Chairman: Jeffrey D. White. Lead organization: Division of Clinical Sciences, National
Cancer Institute. Age range: 18 and over.
Legend for abbreviations:
E = Eastern Cooperative Oncology Group
LIGAND = Ligand Pharmaceuticals, Inc.
MDA = M.D. Anderson Cancer Center
NBSG = National Biotherapy Study Group
NCI = National Cancer Institute
NU = Northwestern University Medical School
SAFR-CT = University of Cape Town
SERAGEN = Seragen, Inc.
YALE-HIC = Yale University
Back to Cancer Control Journal Volume 5
Number 1